Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population

Alap Christy; Rohini Kelkar; Megha Kambli; Jyotsna Naik; Raj Jatale; Pratip Patiyane; Madhuri Bhosale; Kirti Chadha; Nilesh Shah; Puneet Kumar Nigam

doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

2023, Vol: 7, Issue: 6

7 / 6Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Copyright Transfer Form

« Previous Article

Original Research

Online Publishing Date:
10 / 10 / 2021

Int J Med Rev Case Rep. 2021; 5(10): 15-21

doi: 10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population

Alap Christy, Rohini Kelkar, Megha Kambli, Jyotsna Naik, Raj Jatale, Pratip Patiyane, Madhuri Bhosale, Kirti Chadha, Nilesh Shah, Puneet Kumar Nigam.

Abstract
Introduction:
Spike protein antibodies are of prime interest considering their neutralizing capacity for SARS CoV2. Data on seroepidemiology of spike antibody titres in the Indian population is scarce. It's need of the hour to understand the same.
Materials & Method:
We analysed the clinical data of patients who opted for the Quantitative Spike protein IgG antibody test. The data was sub-grouped as per demographic details, vaccination history & history of past COVID infection.
Results:
Overall seropositivity of Spike Antibodies amongst COVAXIN® users was 84% compared to 97.1% of the users who were vaccinated with COVISHIELD®. Breakthrough infection cases were 23% post first dose compared to 0.96% of the post-second dose. Median titres in the group with a history of Covid was 5-6-fold higher compared to the group without a history of infection. Individuals vaccinated with COVISHIELD® produced 2-fold high titres than COVAXIN® in individuals who did not have a known history of past COVID-19 Infection. No significant difference was observed in titres with an increase in dose gap of COVISHIELD®. Non vaccinated individuals with past COVID infection less than 6 months ago showed median 2-fold high titres compared to the ones infected earlier. Conclusions: Both COVISHIELD® and COVAXIN® have proven to produce seroconversion in almost all the subgroups. Evaluation of cellular immunity and protection by non-spike antibodies needs to be evaluated before drawing more meaningful conclusions. Increasing the gap between two doses did not prove to be of advantage. The need for vaccination can be deferred in COVID infected individuals till 6 months, prioritizing more on the naïve population.

Key words: Cellular Immunity, Humoral Immunity, Immunology, Neutralizing Antibody, Spike Antibody

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Alap Christy Articles by Rohini Kelkar Articles by Megha Kambli Articles by Jyotsna Naik Articles by Raj Jatale Articles by Pratip Patiyane Articles by Madhuri Bhosale Articles by Kirti Chadha Articles by Nilesh Shah Articles by Puneet Kumar Nigam
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Christy A, Kelkar R, Kambli M, Naik J, Jatale R, Patiyane P, Bhosale M, Chadha K, Shah N, Nigam PK. Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population. Int J Med Rev Case Rep. 2021; 5(10): 15-21. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

Web Style

Christy A, Kelkar R, Kambli M, Naik J, Jatale R, Patiyane P, Bhosale M, Chadha K, Shah N, Nigam PK. Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population. https://www.mdpub.net/?mno=103968 [Access: April 04, 2024]. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

AMA (American Medical Association) Style

Christy A, Kelkar R, Kambli M, Naik J, Jatale R, Patiyane P, Bhosale M, Chadha K, Shah N, Nigam PK. Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population. Int J Med Rev Case Rep. 2021; 5(10): 15-21. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

Vancouver/ICMJE Style

Christy A, Kelkar R, Kambli M, Naik J, Jatale R, Patiyane P, Bhosale M, Chadha K, Shah N, Nigam PK. Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population. Int J Med Rev Case Rep. (2021), [cited April 04, 2024]; 5(10): 15-21. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

Harvard Style

Christy, A., Kelkar, . R., Kambli, . M., Naik, . J., Jatale, . R., Patiyane, . P., Bhosale, . M., Chadha, . K., Shah, . N. & Nigam, . P. K. (2021) Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population. Int J Med Rev Case Rep, 5 (10), 15-21. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

Turabian Style

Christy, Alap, Rohini Kelkar, Megha Kambli, Jyotsna Naik, Raj Jatale, Pratip Patiyane, Madhuri Bhosale, Kirti Chadha, Nilesh Shah, and Puneet Kumar Nigam. 2021. Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population. International Journal of Medical Reviews and Case Reports, 5 (10), 15-21. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

Chicago Style

Christy, Alap, Rohini Kelkar, Megha Kambli, Jyotsna Naik, Raj Jatale, Pratip Patiyane, Madhuri Bhosale, Kirti Chadha, Nilesh Shah, and Puneet Kumar Nigam. "Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population." International Journal of Medical Reviews and Case Reports 5 (2021), 15-21. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

MLA (The Modern Language Association) Style

Christy, Alap, Rohini Kelkar, Megha Kambli, Jyotsna Naik, Raj Jatale, Pratip Patiyane, Madhuri Bhosale, Kirti Chadha, Nilesh Shah, and Puneet Kumar Nigam. "Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population." International Journal of Medical Reviews and Case Reports 5.10 (2021), 15-21. Print. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

APA (American Psychological Association) Style

Christy, A., Kelkar, . R., Kambli, . M., Naik, . J., Jatale, . R., Patiyane, . P., Bhosale, . M., Chadha, . K., Shah, . N. & Nigam, . P. K. (2021) Seroepidemiology of Spike protein antibodies to SARS CoV-2 in vaccinated & non vaccinated Indian population. International Journal of Medical Reviews and Case Reports, 5 (10), 15-21. doi:10.5455/IJMRCR.Spike-protein-antibodies-SARS-CoV-2

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.

For best results, please use Internet Explorer or Google Chrome.

Contact Information

Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31, Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press.

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500

About International Journal of Medical Reviews and Case Reports

Contact Information

How to cite this article